We are searching data for your request:
Upon completion, a link will appear to access the found materials.
Study: Remdesivir effective against corona disease even after short treatment
Remdesivir is a medication that has been used in many countries for months to treat COVID-19 disease, which is caused by the SARS-CoV-2 coronavirus. It is also used in Germany, for example at the Dresden University Hospital. A study has now shown that the drug is effective against corona disease even after a short treatment.
The corona pandemic is working on strategies to curb the spread of the virus worldwide. So far, there is no effective vaccine - and no drug that is approved against COVID-19. For this reason, medication that has already been developed for other diseases is used, especially in the case of severe disease. Remdesivir is used here in some clinics. And with success, as a new study now shows.
Use of the drug Remdesivir for the treatment of COVID-19 has been studied
According to a recent announcement by the Technical University of Munich (TUM), scientists from eight countries have investigated the use of the drug remdesivir for the treatment of COVID-19 in an international study.
One result of the scientific investigation, in which the Klinikum rechts der Isar at TUM was also involved: The changes in the clinical condition of patients who were treated for five days were comparable to those during a ten-day treatment.
As explained in the announcement, the drug Remdesivir is a so-called RNA polymerase inhibitor and was originally tested for the treatment of patients with Ebola infection.
A number of clinical studies have demonstrated the effectiveness of the drug against the novel coronavirus SARS-CoV-2 in recent months.
After studies in previous studies with remdesivir had proven effective when used over ten days, the researchers wanted to find out whether a shorter treatment period would also be successful.
The results were published in the New England Journal of Medicine (NEJM).
The study has now been expanded to thousands of test subjects
In the international, randomized study, the researchers involved examined the effectiveness and safety of the drug in 397 patients with a proven severe COVID-19 disease.
According to the experts, the study was carried out in eight countries in spring 2020.
According to the information, the patients treated in normal and intensive care units were randomly divided into both groups and received the drug remdesivir intravenously over five or ten days.
The study has now been expanded to include an additional 5,600 test subjects.
Treatment only as long as necessary
According to the announcement, the study found a comparable improvement in clinical condition after five and ten days of therapy. The changes were therefore measured on a seven-point scale.
"The duration of therapy is of great interest for medical care", says private lecturer Dr. Christoph Spinner, who was responsible for the study at the Klinikum rechts der Isar.
"On the one hand, patients are only treated for as long as necessary and, if necessary, can be discharged from the hospital earlier," explains the expert.
“On the other hand, the drug would be available to more people, which is an advantage when production capacity is expected to be limited. Shorter use may also have fewer side effects for the sufferer. ”
According to the researchers, the observed side effects were comparable in both groups and included nausea, acute deterioration in lung function, increased liver values and constipation. (ad)
Author and source information
This text corresponds to the requirements of the medical literature, medical guidelines and current studies and has been checked by medical doctors.
- Technical University of Munich (TUM): Remdesivir effective against Covid-19 even after a short treatment, (accessed: 06.06.2020), Technical University of Munich (TUM)
- Jason D. Goldman, M.D., M.P.H., David C.B. Lye, MB, BS, David S. Hui, MD, Kristen M. Marks, MD, Raffaele Bruno, MD, Rocio Montejano, MD, Christoph D. Spinner, MD, Massimo Galli, MD, Mi-Young Ahn, MD, Ronald G. Nahass, MD, Yao-Shen Chen, MD, Devi SenGupta, MD, et al .: Remdesivir for 5 or 10 Days in Patients with Severe Covid-19; in: New England Journal of Medicine, (published: May 27, 2020), New England Journal of Medicine